Ensign Group (ENSG) and National Healthcare, Corp. (NHC) on Torvanta's measures: ENSG grades higher on 2 of the 4 factor families and NHC on 1.
| ENSG | NHC | |
|---|---|---|
| Value grade | C+ | C |
| Growth grade | B- | C+ |
| Profitability grade | C+ | C+ |
| Momentum grade | C | A- |
| Market value | $10.3B | $3.8B |
| P/E (trailing) | 27.7x | 27.3x |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $5.5B | $1.6B |
| Revenue growth (y/y) | +19% | +7% |
| Operating margin | 8.5% | 9.3% |
| Return on invested capital | 15.3% | 10.3% |
| Free-cash-flow yield | 5.9% | 3.9% |
| Total return, 1 year | -1.4% | +102.2% |
| Total return, 3 years | n/a | n/a |
Full ENSG analysis · Full NHC analysis
Ensign Group (ENSG) and National Healthcare, Corp. (NHC) on Torvanta's measures: ENSG grades higher on 2 of the 4 factor families and NHC on 1. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings ENSG trades at 27.7x and NHC at 27.3x; their value grades are C+ and C against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer